(Q44990505)

English

Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Ard van Sighem

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Claudia Balotta

8

object named as

Claudia Balotta

0 references

Sophie Matheron

object named as

Sophie Matheron

12

0 references

Vicente Soriano

object named as

Vicente Soriano

6

0 references

Alexandra Calmy

7

object named as

Alexandra Calmy

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Florence Damond

9

object named as

Florence Damond

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Geneviève Chêne

11

object named as

Geneviève Chene

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Françoise Brun-Vézinet

10

object named as

Françoise Brun-Vezinet

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1

object named as

Antoine Benard

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

5

object named as

Jean Ruelle

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

3

object named as

Audrey Taieb

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Emília Valadas

4

object named as

Emilia Valadas

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

author name string

ACHIEV2E Collaboration Study Group

13

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

language of work or name

0 references

publication date

1 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1257-1266

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Are fusion inhibitors active against all HIV variants?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Highly active antiretroviral therapy and viral response in HIV type 2 infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR123

21 January 2018

Identifiers

10.1093/CID/CIR123

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44990505&oldid=2060681016"